










Product	Potential Indications	Preclinical	Phase 1	Phase 2	Phase 3
 NGM282 FGF19 Analog	NASH				
 NGM313 (MK-3655) FGFR1c/KLB Agonistic Antibody	NASH, Type 2 Diabetes				
 NGM120 GFRAL Antagonistic Antibody	Cancer Anorexia / Cachexia Syndrome				
 NGM217 Undisclosed	Diabetes				
 NGM621 Undisclosed	Dry Age-Related Macular Degeneration				
 NGM386 GDF15 Analog	Obesity				
 NGM395 GDF15 Analog	Obesity				